round button
Leave a message

欧洲器官排斥预防市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

欧洲器官排斥预防市场 – 行业趋势和 2029 年预测

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Europe
  • 350 页面
  • 桌子數: 421
  • 图号: 56

Europe Prophylaxis Of Organ Rejection Market

市场规模(十亿美元)

CAGR :  % Diagram

Chart Image USD 839.28 Million USD 1,087.24 Million 2022 2029
Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 839.28 Million
Diagram Market Size (Forecast Year)
USD 1,087.24 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

欧洲器官排斥预防市场,按原因(流行病学暴露、抗菌预防、预防其他病原体等)、治疗(门诊免疫抑制剂、住院免疫抑制剂等)、给药途径(口服、静脉注射)、器官(肾、肝、心脏、肺、其他)、患者类型(儿科、成人)、最终用户(医院、诊所家庭医疗保健等)、分销渠道(直接招标、药店等)、国家(英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、比利时、土耳其和欧洲其他地区)、行业趋势和预测到 2029 年。

欧洲预防器官排斥市场

市场分析和见解:欧洲器官排斥预防市场

预计在 2021 年至 2029 年的预测期内,欧洲器官排斥预防市场将实现增长。Data Bridge Market Research 分析,在 2022 年至 2029 年的预测期内,欧洲市场将以 3.4% 的复合年增长率增长,预计到 2029 年将从 2021 年的 8.3928 亿美元达到 10.8724 亿美元。器官移植的普及率上升和免疫抑制剂的使用增加可能是预测期内推动市场需求的主要驱动力。

预防一词是指给予治疗或采取行动来预防疾病。器官排斥的预防是指使用药物预防器官排斥。接受移植的患者必须接受免疫抑制治疗以预防排斥,以确保移植物存活。移植排斥是一个过程,在此过程中,移植接受者的免疫力会下降。目前的排斥预防措施包括使用钙调磷酸酶抑制剂、mTOR 抑制剂、抗代谢药物和皮质类固醇。治疗药物可以改善器官移植的短期后果,但有一定的改善。接受实体器官移植的接受者应服用抗排斥药物。这是因为免疫系统会破坏移植的器官。

推动北美器官排斥预防市场增长的因素包括器官移植的普及、外科手术的增多、接受者人口的增加和产品的推出。然而,预计会制约市场的因素包括移植手术成本的上升、对器官移植缺乏认识以及患者接受移植器官时存在的风险。

  • 另一方面,市场参与者的战略举措、研发的增加以及免疫抑制剂的使用可能为北美器官排斥预防市场的增长提供机会。对熟练专业知识和监管部门批准的需求可能会给北美器官排斥预防市场带来挑战。北美器官排斥预防市场最近出现了一些发展。

欧洲器官排斥预防市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况,请联系我们获取分析师简报,我们的团队将帮助您创建收入影响解决方案以实现您的预​​期目标。

欧洲预防器官排斥市场

欧洲预防器官排斥市场范围和市场规模

分析了欧洲器官排斥预防市场,并按原因、治疗、给药途径、器官、患者类型、最终用户和分销渠道提供了市场规模信息。各细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

  • 根据原因,北美器官排斥预防市场细分为流行病学暴露、抗菌预防、针对其他病原体的预防和其他。2022 年,流行病学暴露部分预计将在北美器官排斥预防市场中占据主导地位,因为美国有直接信息和与器官排斥预防相关的病原体存在
  • 根据治疗方式,北美器官排斥预防市场细分为门诊免疫抑制剂、住院免疫抑制剂和其他。2022 年,门诊免疫抑制剂市场预计将在北美器官排斥预防市场占据主导地位,因为它可以实现对受损细胞的持续和特异性免疫反应,并且环孢菌素在美国和加拿大可用。
  • 根据给药途径,北美器官排斥预防市场分为口服和静脉注射。到 2022 年,由于口服片剂和胶囊的供应量和摄入量增加,口服药物预计将在北美器官排斥预防市场中占据主导地位。
  • 根据器官,北美器官排斥预防市场细分为肾脏、肝脏、心脏、肺脏和其他器官。2022 年,肾脏领域预计将在北美器官排斥预防领域占据主导地位,因为肾衰竭发病率增加,且存在医疗保险等针对接受者保险的报销政策。
  • 根据患者类型,北美器官排斥预防市场分为儿科和成人。2022 年,成人市场预计将在北美器官排斥预防市场中占据主导地位,这是由于成人患者慢性病和遗传病患病率增加、成人免疫系统较弱以及新墨西哥州和美国成人接受者的候补名单比儿童和妇女的候补名单要多
  • 根据最终用户,北美器官排斥预防市场分为医院、诊所、家庭医疗保健和其他。到 2022 年,医院部门预计将主导北美器官排斥预防市场,因为医疗保健水平的提高以及与北美其他医院合作向接受患者提供捐赠器官预计将占据市场主导地位。
  • 根据分销渠道,北美器官排斥预防市场分为直接招标、药店和其他。到 2022 年,由于制药公司对门诊免疫抑制剂的需求激增,预计直接招标部分将主导北美器官排斥预防市场,并且保证付款将主导市场。

欧洲预防器官排斥市场国家级分析

对欧洲器官排斥预防市场进行了分析,并按原因、治疗、给药途径、器官、患者类型、最终用户和分销渠道提供了市场规模信息。

欧洲器官排斥预防市场报告涵盖的国家包括英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、比利时、土耳其和欧洲其他地区。

预计欧洲将在预测期内以复合年增长率增长,因为肺病学领域的研发活动不断增加。预计德国将在欧洲市场占据主导地位。由于主要市场参与者的存在以及欧洲器官排斥预防技术进步的提高,德国是领先国家之一。

报告的国家部分还提供了影响单个市场因素和国内市场法规变化,这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

市场参与者为预防器官排斥而采取的战略举措正在为欧洲预防器官排斥市场创造新的机遇。

欧洲器官排斥预防市场还为您提供每个国家/地区特定行业增长的详细市场分析,包括欧洲器官排斥预防销售、欧洲器官排斥预防发展的影响以及监管环境的变化及其对欧洲器官排斥预防颗粒市场的支持。数据适用于 2020 年至 2021 年的历史时期。

竞争格局和欧洲预防器官排斥市场份额分析

欧洲预防器官排斥市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对欧洲预防器官排斥市场的关注有关。

欧洲提供器官排斥预防药物的主要公司有 Hansa Biopharma、Concord Biotech、Panacea Biotec、WOCKHARDT、SEBELA PHARMACEUTICALS、Accord-UK Ltd、Veloxis Pharmaceuticals, Inc、Astellas Pharma Inc、Novartis AG、Bristol-Myers Squibb Company、Dr Reddy's Laboratories, Ltd、Viatris Inc、Strides Pharma Science Limited、Glenmark、Biocon、Pfizer Inc、Hikma Pharmaceuticals PLC、AbbVie Inc、Amneal Pharmaceuticals LLC、Zydus Pharmaceuticals, Inc.、CSL Behring 等。

市场参与者的战略举措以及欧洲预防器官排斥市场的新技术进步正在弥补药品方面的差距。

例如,

  • 2020 年 11 月,Concord Biotech 和 Lupin 获得了美国 FDA 批准的仿制免疫抑制剂胶囊。获得的批准将增加用于治疗器官排斥的免疫抑制剂胶囊的销量。获得的批准确保了仿制免疫抑制剂胶囊的上市后批准,并使其在药店和零售店有售。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 BY CAUSE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 EUROPE PROPHYLAXIS OF ORGAN REJECTION: EPIDEMIOLOGY SNAPSHOT

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISE IN PREVALENCE OF ORGAN TRANSPLANTATIONS

5.1.2 RISE IN CHRONIC DISEASES

5.1.3 RISE IN CLINICAL TRIALS

5.1.4 RISE IN RECIPIENT PATIENTS

5.1.5 PRODUCT APPROVALS

5.2 RESTRAINTS

5.2.1 RISE IN COST OF TRANSPLANTATION PROCEDURE

5.2.2 LACK OF AWARENESS ABOUT ORGAN TRANSPLANTATION

5.2.3 RISKS INCLUDED WITH THE PATIENT RECEIVES TRANSPLANTED ORGAN

5.2.4 ETHICAL ISSUES RELATED TO ORGAN TRANSPLANTATION

5.3 OPPORTUNITIES

5.3.1 RISE IN RESEARCH AND DEVELOPMENTS

5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

5.3.3 RISE IN USE OF IMMUNOSUPPRESSANT

5.4 CHALLENGES

5.4.1 SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE USE OF PROPHYLAXIS OF ORGAN REJECTION

5.4.2 STRINGENT REGULATIONS

6 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE

6.1 OVERVIEW

6.2 EPIDEMIOLOGIC EXPOSURE

6.2.1 HOSPITAL EXPOSURE

6.2.2 COMMUNITY EXPOSURE

6.3 ANTIBACTERIAL PROPHYLAXIS

6.3.1 POST-TRANSPLANT PROPHYLAXIS

6.3.2 PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS

6.4 PROPHYLAXIS AGAINST OTHER PATHOGENS

6.5 OTHERS

7 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 OUTPATIENT IMMUNOSUPPRESSANT

7.2.1 CALCINEURIN INHIBITORS

7.2.1.1 CYCLOSPORINE

7.2.1.2 TACROLIMUS

7.2.1.2.1 IMMEDIATE RELEASE

7.2.1.2.2 EXTENDED RELEASE

7.2.2 CORTICOSTEROIDS

7.2.2.1 METHYLPREDNISOLONE

7.2.2.2 PREDNISONE

7.2.2.3 OTHERS

7.2.3 MYCOPHENOLIC ACIDS

7.2.3.1 MYCOPHENOLATE MOFETIL

7.2.3.2 MYCOPHENOLATE SODIUM

7.2.4 MTOR INHIBITORS

7.2.4.1 SIROLIMUS

7.2.4.2 EVEROLIMUS

7.2.5 AZATHIOPRINE

7.2.6 OTHERS

7.3 INPATIENT IMMUNOSUPPRESSANT

7.3.1 BELATACEPT

7.3.2 BASILIXIMAB

7.3.3 OTHERS

7.4 OTHERS

7.4.1 ERYTHROPOIESIS-STIMULATING AGENTS

7.4.1.1 ERYTHROPOIETIN

7.4.1.2 DARBEPOETIN

7.4.2 ANTI-VIRAL AGENTS

7.4.2.1 VALGANCICLOVIR

7.4.2.2 LAMIVUDINE

7.4.2.3 ADEFOVIR

7.4.2.4 OTHERS

7.4.3 OTHERS

8 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 ORAL

8.2.1 TABLET

8.2.1.1 IMMEDIATE RELEASE

8.2.1.2 EXTENDED-RELEASE

8.2.2 ORAL SOLUTION

8.2.3 OTHERS

8.3 INTRAVENOUS

9 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN

9.1 OVERVIEW

9.2 KIDNEY

9.3 LIVER

9.4 HEART

9.5 LUNG

9.6 OTHERS

10 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 ADULTS

10.3 PEDIATRIC

11 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICS

11.4 HOME HEALTHCARE

11.5 OTHERS

12 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDERS

12.3 PHARMACY STORES

12.3.1 HOSPITAL PHARMACY

12.3.2 RETAIL PHARMACY

12.3.3 ONLINE PHARMACY

12.4 OTHERS

13 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION

13.1 EUROPE

13.1.1 FRANCE

13.1.2 SPAIN

13.1.3 U.K.

13.1.4 ITALY

13.1.5 GERMANY

13.1.6 POLAND

13.1.7 NETHERLANDS

13.1.8 SWEDEN

13.1.9 AUSTRIA

13.1.10 SWITZERLAND

13.1.11 NORWAY

13.1.12 HUNGARY

13.1.13 DENMARK

13.1.14 IRELAND

13.1.15 GREECE

13.1.16 LITHUANIA

13.1.17 REST OF EUROPE

14 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 QUESTIONNAIRE

16 RELATED REPORTS

表格列表

TABLE 1 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 2 EUROPE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 4 EUROPE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 6 EUROPE PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 EUROPE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 EUROPE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 EUROPE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 13 EUROPE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 14 EUROPE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 15 EUROPE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 16 EUROPE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 EUROPE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 EUROPE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 28 EUROPE KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 34 EUROPE ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 EUROPE PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 37 EUROPE HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 EUROPE CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 EUROPE HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 EUROPE DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 EUROPE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 44 EUROPE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 46 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 47 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 48 EUROPE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 49 EUROPE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 50 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 EUROPE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 EUROPE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 EUROPE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 EUROPE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 EUROPE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 56 EUROPE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 57 EUROPE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 58 EUROPE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 EUROPE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 60 EUROPE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 61 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 62 EUROPE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 63 EUROPE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 64 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 65 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 66 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 67 EUROPE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 68 EUROPE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 FRANCE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 70 FRANCE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 71 FRANCE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 72 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 FRANCE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 FRANCE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 FRANCE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 FRANCE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 FRANCE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 FRANCE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 FRANCE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 FRANCE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 FRANCE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 FRANCE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 84 FRANCE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 85 FRANCE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 86 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 87 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 88 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 89 FRANCE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 90 FRANCE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 SPAIN PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 92 SPAIN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 93 SPAIN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 94 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 SPAIN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 SPAIN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 97 SPAIN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 SPAIN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 99 SPAIN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 100 SPAIN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 SPAIN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 SPAIN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 SPAIN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 SPAIN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 106 SPAIN ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 107 SPAIN TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 108 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 109 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 110 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 111 SPAIN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 112 SPAIN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 113 U.K. PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 114 U.K. EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 115 U.K. ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 116 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 117 U.K. OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 U.K. CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 U.K. TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 U.K. MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 U.K. MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 U.K. CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 U.K. INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 U.K. OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 U.K. ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 126 U.K. ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 127 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 128 U.K. ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 129 U.K. TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 130 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 131 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 132 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 133 U.K. PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 134 U.K. PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 135 ITALY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 136 ITALY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 137 ITALY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 138 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 139 ITALY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 140 ITALY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 ITALY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 ITALY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 143 ITALY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 144 ITALY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 145 ITALY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 146 ITALY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 147 ITALY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 148 ITALY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 150 ITALY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 151 ITALY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 152 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 153 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 154 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 155 ITALY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 156 ITALY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 157 GERMANY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 158 GERMANY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 159 GERMANY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 160 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 161 GERMANY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 162 GERMANY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 163 GERMANY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 164 GERMANY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 165 GERMANY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 166 GERMANY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 167 GERMANY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 168 GERMANY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 169 GERMANY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 170 GERMANY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 171 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 172 GERMANY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 173 GERMANY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 174 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 175 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 176 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 177 GERMANY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 178 GERMANY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 179 POLAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 180 POLAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 181 POLAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 182 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 183 POLAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 184 POLAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 185 POLAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 186 POLAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 187 POLAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 188 POLAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 189 POLAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 190 POLAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 191 POLAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 192 POLAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 193 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 194 POLAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 195 POLAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 196 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 197 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 198 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 199 POLAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 200 POLAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 201 NETHERLANDS PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 202 NETHERLANDS EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 203 NETHERLANDS ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 204 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 205 NETHERLANDS OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 206 NETHERLANDS CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 207 NETHERLANDS TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 208 NETHERLANDS MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 209 NETHERLANDS MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 210 NETHERLANDS CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 211 NETHERLANDS INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 212 NETHERLANDS OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 213 NETHERLANDS ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 214 NETHERLANDS ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 215 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 216 NETHERLANDS ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 217 NETHERLANDS TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 218 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 219 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 220 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 221 NETHERLANDS PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 222 NETHERLANDS PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 223 SWEDEN PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 224 SWEDEN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 225 SWEDEN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 226 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 227 SWEDEN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 228 SWEDEN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 229 SWEDEN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 230 SWEDEN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 231 SWEDEN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 232 SWEDEN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 233 SWEDEN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 234 SWEDEN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 235 SWEDEN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 236 SWEDEN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 237 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 238 SWEDEN ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 239 SWEDEN TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 240 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 241 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 242 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 243 SWEDEN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 244 SWEDEN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 245 AUSTRIA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 246 AUSTRIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 247 AUSTRIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 248 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 249 AUSTRIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 250 AUSTRIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 251 AUSTRIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 252 AUSTRIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 253 AUSTRIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 254 AUSTRIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 255 AUSTRIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 256 AUSTRIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 257 AUSTRIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 258 AUSTRIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 259 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 260 AUSTRIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 261 AUSTRIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 262 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 263 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 264 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 265 AUSTRIA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 266 AUSTRIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 267 SWITZERLAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 268 SWITZERLAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 269 SWITZERLAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 270 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 271 SWITZERLAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 272 SWITZERLAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 273 SWITZERLAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 274 SWITZERLAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 275 SWITZERLAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 276 SWITZERLAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 277 SWITZERLAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 278 SWITZERLAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 279 SWITZERLAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 280 SWITZERLAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 281 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 282 SWITZERLAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 283 SWITZERLAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 284 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 285 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 286 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 287 SWITZERLAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 288 SWITZERLAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 289 NORWAY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 290 NORWAY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 291 NORWAY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 292 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 293 NORWAY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 294 NORWAY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 295 NORWAY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 296 NORWAY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 297 NORWAY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 298 NORWAY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 299 NORWAY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 300 NORWAY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 301 NORWAY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 302 NORWAY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 303 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 304 NORWAY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 305 NORWAY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 306 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 307 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 308 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 309 NORWAY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 310 NORWAY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 311 HUNGARY PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 312 HUNGARY EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 313 HUNGARY ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 314 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 315 HUNGARY OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 316 HUNGARY CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 317 HUNGARY TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 318 HUNGARY MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 319 HUNGARY MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 320 HUNGARY CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 321 HUNGARY INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 322 HUNGARY OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 323 HUNGARY ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 324 HUNGARY ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 325 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 326 HUNGARY ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 327 HUNGARY TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 328 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 329 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 330 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 331 HUNGARY PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 332 HUNGARY PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 333 DENMARK PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 334 DENMARK EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 335 DENMARK ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 336 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 337 DENMARK OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 338 DENMARK CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 339 DENMARK TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 340 DENMARK MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 341 DENMARK MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 342 DENMARK CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 343 DENMARK INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 344 DENMARK OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 345 DENMARK ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 346 DENMARK ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 347 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 348 DENMARK ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 349 DENMARK TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 350 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 351 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 352 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 353 DENMARK PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 354 DENMARK PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 355 IRELAND PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 356 IRELAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 357 IRELAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 358 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 359 IRELAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 360 IRELAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 361 IRELAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 362 IRELAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 363 IRELAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 364 IRELAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 365 IRELAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 366 IRELAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 367 IRELAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 368 IRELAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 369 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 370 IRELAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 371 IRELAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 372 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 373 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 374 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 375 IRELAND PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 376 IRELAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 377 GREECE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 378 GREECE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 379 GREECE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 380 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 381 GREECE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 382 GREECE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 383 GREECE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 384 GREECE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 385 GREECE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 386 GREECE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 387 GREECE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 388 GREECE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 389 GREECE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 390 GREECE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 391 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 392 GREECE ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 393 GREECE TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 394 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 395 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 396 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 397 GREECE PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 398 GREECE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 399 LITHUANIA PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 400 LITHUANIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 401 LITHUANIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 402 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 403 LITHUANIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 404 LITHUANIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 405 LITHUANIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 406 LITHUANIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 407 LITHUANIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 408 LITHUANIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 409 LITHUANIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 410 LITHUANIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 411 LITHUANIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 412 LITHUANIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 413 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 414 LITHUANIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 415 LITHUANIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 416 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 417 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 418 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY END USER, 2020-2029 (USD MILLION)

TABLE 419 LITHUANIA PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 420 LITHUANIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 421 REST OF EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT, BY CAUSE, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

FIGURE 2 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: DBMR POSITION GRID

FIGURE 8 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: END USER COVERAGE GRID

FIGURE 10 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED PREVALENCE OF ORGAN TRANSPLANTATION, RISE IN RECIPIENT PATIENTS, AND PRODUCT APPPROVALS ARE EXPECTED TO DRIVE EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 TO 2029

FIGURE 13 EPIDEMIOLOGIC EXPOSURE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 & 2029

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PROPHYLAXIS OF ORGAN REJECTION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 15 EUROPE PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE, 2021

FIGURE 16 EUROPE PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE REGIONAL LEVEL, 2021

FIGURE 17 EUROPE PROPHYLAXIS OF ORGAN REJECTION: PREVALENCE (2018-2021) AT REGIONAL LEVEL SNAPSHOT

FIGURE 18 EUROPE PROPHYLAXIS OF ORGAN REJECTION: SURVIVAL OF PATIENT SNAPSHOT

FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET

FIGURE 20 INCREASE COUNT OF KIDNEY TRANSPLANTATIONS IN THE U.S., 2020

FIGURE 21 TOTAL NUMBER OF ORGAN TRANSPLANTATION IN THE EUROPE SCENARIO, 2020

FIGURE 22 TOTAL NUMBER OF PATIENTS ON WAITING LIST VS TRANSPLANTS PERFORMED BY ORGAN IN 2020

FIGURE 23 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2021

FIGURE 24 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2020-2029 (USD MILLION)

FIGURE 25 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, CAGR (2022-2029)

FIGURE 26 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 27 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2021

FIGURE 28 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2020-2029 (USD MILLION)

FIGURE 29 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 30 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 31 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 32 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 33 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 34 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2021

FIGURE 36 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2020-2029 (USD MILLION)

FIGURE 37 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, CAGR (2022-2029)

FIGURE 38 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, LIFELINE CURVE

FIGURE 39 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2021

FIGURE 40 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2020-2029 (USD MILLION)

FIGURE 41 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 42 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 43 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2021

FIGURE 44 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 45 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, CAGR (2022-2029)

FIGURE 46 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 48 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 49 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 50 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: SNAPSHOT (2021)

FIGURE 52 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY COUNTRY (2021)

FIGURE 53 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 54 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 55 EUROPE PROPHYLAXIS OF ORGAN TRANSPLANT MARKET: BY CAUSE (2022-2029)

FIGURE 56 EUROPE PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

The market is segmented based on , By Cause (Epidemiologic Exposure, Antibacterial Prophylaxis, Prophylaxis Against Other Pathogens And Others), Treatment (Outpatient Immunosuppressant, Inpatient Immunosuppressant And Others), Route Of Administration (Oral, Intravenous), Organ (Kidney, Liver, Heart, Lung, Others), Patient Type (Pediatric, Adults), End User (Hospitals, Clinic Home Healthcare And Others), Distribution Channel (Direct Tender, Pharmacy Stores And Others), Country (U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey And Rest Of Europe), Industry Trends And Forecast To 2029. .
The Europe Prophylaxis Of Organ Rejection Market size was valued at USD 839.28 USD Million in 2021.
The Europe Prophylaxis Of Organ Rejection Market is projected to grow at a CAGR of 3.4% during the forecast period of 2022 to 2029.
Testimonial
a